Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies

(2016) T. M. Shaver et al.   CANCER RESEARCH

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

(2016) Ashley Cimino-Mathews et al.   HUMAN PATHOLOGY

Malignant Melanoma of the Nail Apparatus

(2016) Ryan C. Romano et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Cytogenetic Analysis of JAZF1, PHF1, and YWHAE in Endometrial Stromal Tumors

(2016) Jennelle C. Hodge et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

(2016) Woo Young Sun et al.   Journal of Translational Medicine

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

(2016) Justin M. Balko et al.   Science Translational Medicine

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS

(2016) Mehrad Tavallai et al.   Oncotarget

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

(2015) K. P. Patel et al.   BLOOD

Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes

(2015) Hee Jin Lee et al.   BREAST CANCER RESEARCH AND TREATMENT

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

(2015) F. Sabbatino et al.   CLINICAL CANCER RESEARCH

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antagonists of PD-1 and PD-L1 in Cancer Treatment

(2015) Evan J. Lipson et al.   SEMINARS IN ONCOLOGY

Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer

(2015) Min Soo Kim et al.   Oncotarget

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

(2015) Michael T. Barrett et al.   Oncotarget

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

(2014) Y. Hao et al.   CLINICAL CANCER RESEARCH

The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade

(2014) A. Ribas et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts

(2014) Anton Neschadim et al.   ENDOCRINE-RELATED CANCER

Targeting the relaxin hormonal pathway in prostate cancer

(2014) Anton Neschadim et al.   INTERNATIONAL JOURNAL OF CANCER

PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells

(2014) Hatem Soliman et al.   PLoS One

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

(2013) A. Quintas-Cardama et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma

(2012) Yanli Luo et al.   PATHOLOGY & ONCOLOGY RESEARCH

Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

(2011) H. Xin et al.   CANCER RESEARCH

Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy

(2011) Chun Hing Tse et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and functional analysis of 9p24 amplified genes in human breast cancer

(2011) J Wu et al.   ONCOGENE

Advancing a clinically relevant perspective of the clonal nature of cancer

(2011) C. Ruiz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome

(2010) Matthias Choschzick et al.   MODERN PATHOLOGY

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

(2009) F. Andre et al.   CLINICAL CANCER RESEARCH

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

(2009) I-Tien Yeh et al.   MODERN PATHOLOGY

Triple-Negative Breast Cancer: Risk Factors to Potential Targets

(2008) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Polysomy 17 and HER-2 Amplification: True, True, and Unrelated

(2008) Carol L. Rosenberg   JOURNAL OF CLINICAL ONCOLOGY

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing

(2008) Isabelle Vanden Bempt et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY